|
| 37104137 | Toward Practical Integration of Omic and Imaging Data in Co-Clinical Trials. | Tomography | 2023 |
| 36408668 | The Aetion Coalition to Advance Real-World Evidence through Randomized Controlled Trial Emulation Initiative: Oncology. | Clin Pharmacol Ther | 2023 |
| 37676964 | Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. | Science | 2023 |
| 37587913 | Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins. | Cancer Res Commun | 2023 |
| 37652539 | Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial). | J Nucl Med | 2023 |
| 36716289 | Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis. | | 2023 |
| 36585450 | Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. | Nat Cancer | 2023 |
| 37467106 | High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer. | Cell Rep | 2023 |
| 37207306 | Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer. | | 2023 |
| 36945501 | Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. | medRxiv | 2023 |
| 37195235 | A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. | Clin Cancer Res | 2023 |
| 37170847 | Margetuximab in HER2-positive metastatic breast cancer. | | 2023 |
| 34645649 | Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER/HER2 Breast Cancer. | Clinical Cancer Research | 2022 |
| 36001024 | Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. | Cancer Discov | 2022 |
| 35737918 | Elacestrant and the Promise of Oral SERDs. | Journal of Clinical Oncology | 2022 |
| 35860837 | Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. | Therapeutic Advances in Medical Oncology | 2022 |
| 36619972 | Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach. | iScience | 2022 |
| 35173164 | Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. | NPJ Breast Cancer | 2022 |
| 34470810 | Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. | Clin Cancer Res | 2021 |
| 34080777 | Lumpectomy followed by radiation improves survival in HER2 positive and triple-negative breast cancer with high tumor-infiltrating lymphocytes compared to mastectomy alone. | Cancer Medicine | 2021 |
| 33810205 | Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. | Cancers | 2021 |
| 34077270 | Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. | J Clin Oncol | 2021 |
| 34173924 | Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. | Breast Cancer Res Treat | 2021 |
| 34120223 | Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). | Breast Cancer Res Treat | 2021 |
| 33536276 | Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. | Clin Cancer Res | 2021 |
| 33999652 | Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. | J Clin Oncol | 2021 |
| 34045483 | Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models. | npj Breast Cancer | 2021 |
| 34515904 | Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer. | Breast Cancer Research and Treatment | 2021 |
| 34618555 | Breast Cancer Prevention: Where Are We? | JCO Oncology Practice | 2021 |
| 31037288 | HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. | J Natl Cancer Inst | 2020 |
| 32000054 | HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. | | 2020 |
| 31558424 | Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. | Clin Breast Cancer | 2020 |
| 31662331 | TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. | Clin Cancer Res | 2020 |
| 31653641 | Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. | Clin Cancer Res | 2020 |
| 32798689 | TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. | Ann Oncol | 2020 |
| 34505091 | Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases. | Current Problems in Cancer: Case Reports | 2020 |
| 30721110 | TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. | J Clin Oncol | 2019 |
| 30523750 | Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. | J Clin Oncol | 2019 |
| 30860945 | TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. | J Clin Oncol | 2019 |
| 31420371 | Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer. | Mol Cancer Res | 2019 |
| 31218477 | Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. | Breast Cancer Research and Treatment | 2019 |
| 30903140 | A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. | Ann Oncol | 2019 |
| 29578538 | Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. | Nat Med | 2018 |
| 30106636 | First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Tr | Journal of Clinical Oncology | 2018 |
| 29443653 | Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. | J Clin Oncol | 2018 |
| 29128193 | Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27. | Clin Breast Cancer | 2018 |
| 29110152 | Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. | Breast Cancer Res Treat | 2018 |
| 28224382 | Retrospective review of genomic testing in breast cancer: Does it improve outcome? | Breast Cancer Research and Treatment | 2017 |
| 28687441 | De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. | Breast | 2017 |
| 28487443 | HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2<sup>+</sup> Breast Cancer. | Clin Cancer Res | 2017 |